Influence of environmental temperature on incidence of indinavir- related nephrolithiasis

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 422-425

  Martínez, Esteban ^a,b   Leguizamón, Marcelo ^a   Mallolas, José ^a   Miró, José M ^a   Gatell, José M ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR;

ARTICLE; ATMOSPHERIC PRESSURE; DRUG ELIMINATION; ENVIRONMENTAL TEMPERATURE; FLUID INTAKE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMIDITY; INCIDENCE; NEPHROLITHIASIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0032776819     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520226     Document Type: Article

References (22)

1. 1. Crixivan® (indinavir sulfate) product monograph [package insert]. West Point, Pennsylvania: Merck, 1997.
2. 2. Kopp JB, Miller KD, Mican JAM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127: 119-25.
3. 3. Grunke M. Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with indinavir. Clin Infect Dis 1997; 25:1270-1.
4. 4. Bach MC, Godofsky EW. Indinavir nephrolithiasis in warm climates. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:296-7.
5. 5. Daudon M, Estépa L, Viard JP, Jungers P. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet 1997;349: 1294-5.
6. 6. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-92.
7. 7. Pak CYC. Kidney stones. Lancet 1998;351:1797-801.
8. 8. Mallolas J, Tortajada C, Martínez E, Pumarola T, Gatell JM, Soriano E. Efficacy and tolerance of indinavir twice daily [abstract no 25]. Clin Infect Dis 1997;25:397.
9. 9. Consensus conference. Prevention and treatment of kidney stones. JAMA 1988;260:977-81.
10. 10. Bailar JC III, Mosteller F. Medical uses of statistics. Waltham, Massachusetts: NEJM Books, Massachusetts Medical Society, 1986.
11. 11. Stek M Jr, Fretz KL, Ikeda LS, Bradstreet DC, McCauley JA. Nephrolithiasis with indinavir-treated advanced AIDS patients in a large compassionate use program [abstract no 440]. In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection (Hamburg, Germany). Hamburg, Germany: European AIDS Clinical Society, 1997.
12. 12. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
13. 13. Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS 1998;12:F249-54.
14. 14. Dieleman J, Gyssens IC, van der Ende MEM, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999;13:473-8.
15. 15. Nguyen BY, Haas DW, Ramirez-Ronda C, et al. Thirty two week follow-up of indinavir sulfate administered q8 hours versus q12 hours in combination with zidovudine and lamivudine [abstract no 374]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retroviruses and Human Health, 1998.
16. 16. Robertson WG, Peacock M. Epidemiological factors in the genesis of calcium-containing urinary stones. In: Linari F, Bruno M, Fruttero B, Marangella M, eds. Proceedings of the Second International Symposium on Metabolic, Physico-Chemical and Therapeutical Aspects of Urolithiasis (Milan, Italy). Milan, Italy: Wichtig, 1983:5-20.
17. 17. Parry ES, Lister IS. Sunlight and hypercalciuria. Lancet 1975;1:1063.
18. 18. al-Hadramy MS. Seasonal variations of urinary stone colic in Arabia. Journal of the Pakistan Medical Association 1997;47:281-4.
19. 19. Borghi L, Meschi T, Amato F, Novarini A, Romanelli A, Cigala F. Hot occupation and nephrolithiasis. J Urol 1993;150:1757-60.
20. 20. Frank M, De Vries A. Prevention of urolithiasis: education to adequate fluid intake in a new town situated in the Judean Desert Mountains. Arch Environ Health 1966;13:625-30.
21. 21. Michl G, Herfort O, Walli R, Anders HJ, Goebel FD. Incidence and risk factors of crystalluria in patients treated with indinavir [abstract no 442]. In: Program and abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV Infection (Hamburg, Germany). Hamburg, Germany: European AIDS Clinical Society, 1997.
22. 22. Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS 1998;12:2433-7.